Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Pharmacogenomics Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedPresbyterian Health PlanPolicy 30.0

    Pharmacogenomics Testing, Behavioral Health for Medicare

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 30.0 alerts

    Get alerted when Policy 30.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs limited coverage and prior authorization for pharmacogenomics testing, including single-gene tests, multigene panels, and combinatorial tests. Medicare coverage follows specified contractor guidance; testing is non-covered and investigational for Medicaid and Commercial members.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyPharmacogenomics Testing, Behavioral Health for Medicare
    Policy CodePolicy 30.0
    Change TypeModified
    Effective DateN/A
    Last ReviewMay 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for pharmacogenomics testing through Pres Online.
    SourceLink
    POLICY UPDATE CHANGES

    Medicare coverage now follows Novitas pharmacogenomics LCD L39063 and related article A58801, with LCD L38435 and related article A58395 also identified as applicable guidance.

    Multiple molecular pathology and proprietary pharmacogenomics codes were added or updated, including codes requiring prior authorization.

    IDgenetix code 0411U was designated investigational and non-covered for non-Medicare products while remaining subject to case-by-case Medicare review.

    GeneSight Psychotropic code 0345U was designated investigational and non-covered for Medicare, Medicaid, and Commercial products.

    Deleted code 0033U was removed from the policy effective January 1, 2026.

    Codes 0173U and 0175U were returned from the Laboratory Benefit Management policy and require prior authorization for all lines of business.

    Codes 0411U and 0345U remain configured as investigational and experimental for all lines of business.

    The policy continues Medicare-only coverage and requires prior authorization for listed pharmacogenomic codes except for specified no-prior-authorization codes.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PA requiredGeneral utilization-management requirement
    MedicareLine of business with policy-based coverage consideration
    Medicaid and CommercialLines of business where testing is investigational and non-covered
    2Named tests explicitly identified as non-covered
    33Codes requiring prior authorization
    4Codes with no prior authorization requirement

    Coverage Criteria

    General PGx Medical Necessity

    Pharmacogenomic testing is medically necessary only when ALL of the following requirements are met:

    ALL of the following

    • The test demonstrates analytical validity through a required technical assessment.
    • The test demonstrates clinical validity through a required technical assessment.
    • The test demonstrates clinical utility through a required technical assessment.
    • The test is evaluated under applicable policies for germline genetic testing, because pharmacogenomic tests are considered germline tests.

    Medicare Coverage Guidance

    For Medicare, coverage is determined under the applicable Medicare contractor LCD and related article guidance.

    ONE of the following Medicare contractor pathways applies

    • Novitas LCD Pharmacogenomics Testing (L39063) and related LCA (A58801).
    • MolDX: Pharmacogenomics Testing LCD (L38435) and related LCA (A58395), including the Wisconsin MolDX pathway.

    Medicare Coverage and Authorization

    Medicare coverage and authorization are subject to ALL of the following operational requirements:

    ALL of the following

    • Coverage is available for Medicare only; pharmacogenomic testing is non-covered and investigational for Medicaid and Commercial lines of business.
    • The requested test meets the applicable Medicare contractor LCD/LCA criteria and the general PGx medical-necessity requirements.
    • Prior authorization is obtained when required. Submit requests through Pres Online at https://ds.phs.org/preslogin/index.jsp.
    • Prior authorization is required for the following codes: 81226, 81381, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 81479, 81227, 81231, 81232, 81247, 0286U, 81401, 81406, 81283, 81306, 81328, 81350, 81355, 0029U, 0349U, 0392U, 0423U, 0193U, 81230, 81346, 81407, 0031U, 0032U, 0419U, 0030U, 0034U, 0173U, and 0175U.

    Pharmacogenomic testing is non-covered for Medicaid and Commercial lines of business. It is considered investigational and is not a covered benefit.

    IDgenetix (code 0411U) is non-covered and considered investigational and experimental for Medicare, Medicaid, and Commercial lines of business.

    GeneSight® Psychotropic by Assurex Health, Inc./Myriad Genetics, Inc. (code 0345U) is non-covered and considered investigational and experimental for Medicare, Medicaid, and Commercial lines of business.

    Pharmacogenomic testing is a non-covered benefit for Commercial and Medicaid members. Coverage benefits are limited to Medicare and remain subject to applicable Medicare contractor guidance and policy criteria.

    Codes 0411U and 0345U are considered investigational and experimental for all lines of business.

    Code 0419U is non-covered because it is outside the relevant gene/drug association table representing drug-metabolizing enzyme associations from CPIC and FDA sources.

    Testing that lacks analytical validity, clinical validity, or clinical utility is not reasonable and necessary and is non-covered.

    Covered, Non-Covered, and Managed Codes

    Codes relevant to behavioral-health gene/drug associations per Novitas LCA A58801CPT
    81225Gene CYP2C19 (cytochrome p450, family 2, subfamily c, polypeptide 19) (EG, drug metabolism), gene analysis, common variants (EG, *2, *3, *4, *8, *17).
    81226CYP2D6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (EG, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN).
    81374HLA CLASS I TYPING, LOW RESOLUTION (EG, ANTIGEN EQUIVALENTS); ONE ANTIGEN EQUIVALENT (EG, B*27), EACH.
    81381HLA CLASS I TYPING, HIGH RESOLUTION (IE, ALLELES OR ALLELE GROUPS); ONE ALLELE OR ALLELE GROUP (EG, B*57:01P), EACH.
    81418Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis.
    0070UCYP2D6 gene analysis, common and select rare variants.
    0071UCYP2D6 gene analysis, full gene sequence.
    0072UCYP2D6 gene analysis, targeted sequence analysis for CYP2D6-2D7 hybrid gene.
    0073UCYP2D6 gene analysis, targeted sequence analysis for CYP2D7-2D6 hybrid gene.
    0076UCYP2D6 gene analysis, targeted sequence analysis for 3' gene duplication/multiplication.
    1–10 of 13
    1/2
    Codes not relevant to behavioral-health gene/drug associations per Novitas LCA A58801CPT
    81479Unlisted Molecular Pathology Procedure.
    81227CYP2C9 gene analysis, common variants.
    81231CYP3A5 gene analysis, common variants.
    81232DPYD gene analysis, common variant(s).
    81247G6PD gene analysis; common variant(s).
    0193URed cell antigen JR blood group genotyping; ABCG2 exons 2-26.
    0286UCEP72, NUDT15, and TPMT gene analysis, common variants.
    81401Molecular pathology procedure, Level 2.
    81406Molecular pathology procedure, Level 7.
    81220CFTR gene analysis; common variants.
    1–10 of 14
    1/2
    Non-covered pharmacogenomic testing codes per Novitas LCA A58395 and WPS A58395CPTNot Covered
    81230CYP3A4 gene common variants.
    81346TYMS gene analysis, common variant(s).
    81355VKORC1 gene analysis, common variants.
    81407Molecular pathology procedure, Level 8.
    0031UCYP1A2 gene analysis, common variants.
    0032UCOMT gene analysis, c.472G>A (rs4680) variant.
    0173UPsychiatry genomic analysis panel for depression or anxiety, variant analysis of 14 genes.
    0175UPsychiatry genomic analysis panel for depression or anxiety, variant analysis of 15 genes.
    0345UPsychiatry genomic analysis panel for depression, anxiety, or ADHD, variant analysis of 15 genes, including CYP2D6 deletion/duplication analysis.
    0411UIDgenetix psychiatry genomic analysis panel for depression, anxiety, or ADHD, variant analysis of 15 genes, including CYP2D6 deletion/duplication analysis.
    1–10 of 11
    1/2
    Codes requiring prior authorizationCPT
    81226Pharmacogenomics testing code
    81381Pharmacogenomics testing code
    81418Pharmacogenomics testing code
    0070UPharmacogenomics testing code
    0071UPharmacogenomics testing code
    0072UPharmacogenomics testing code
    0073UPharmacogenomics testing code
    0074UPharmacogenomics testing code
    0075UPharmacogenomics testing code
    0076UPharmacogenomics testing code
    1–10 of 38
    1/4
    Codes with no prior authorization requirementCPTCovered
    81225Pharmacogenomics testing code
    81374Pharmacogenomics testing code
    81335Pharmacogenomics testing code
    0411UIDgenetix pharmacogenomics test
    Investigational and experimental for all lines of businessCPTExperimental
    0411UIDgenetix pharmacogenomics test
    0345UGeneSight Psychotropic testing
    Non-covered codeCPTNot Covered
    0419UNeuropsychiatry-related testing code
    Removed deleted codeCPT
    0033UDeleted laboratory code
    Codes previously moved to the Laboratory Benefit Management policyCPT
    81377Laboratory testing code
    81383Laboratory testing code
    81408Laboratory testing code
    0117ULaboratory testing code
    0173UPLA laboratory testing code
    0175UPLA laboratory testing code
    Codes removed from the policyCPT
    0289ULaboratory testing code
    0290ULaboratory testing code
    0291ULaboratory testing code
    0292ULaboratory testing code
    0293ULaboratory testing code
    0294ULaboratory testing code
    Cystic fibrosis code with no prior authorization requirementCPTCovered
    81220Cystic fibrosis testing code
    Genomic Sequence Analysis Panel
    Minimum panel sizeAt least 6 genes
    Required geneCYP2C19
    Required gene and analysisCYP2D6, including CYP2D6 duplication/deletion analysis

    Authorization, Documentation, and Billing Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for pharmacogenomics testing requests. Submit requests through Pres Online.

    • Use Pres Online: https://ds.phs.org/preslogin/index.jsp
    Prior Authorization

    Selected Codes Require Prior Authorization

    The following selected codes require prior authorization for all lines of business.

    • 81306 — NUDT15 gene analysis
    • 81418 — Pharmacogenomic multigene analysis
    • 0193U — Pharmacogenomic testing

    Policy Background

    Pharmacogenomics testing evaluates inherited genetic variation that may affect medication metabolism, treatment response, and adverse effects. The policy addresses single-gene tests, multigene panels, and combinatorial tests, including behavioral-health-related gene-drug associations. These are germline tests and must demonstrate analytical validity, clinical validity, and clinical utility through a required technical assessment. Results should not be used as the sole basis for prescribing decisions.

    Key Terms

    Pharmacogenomics Testing (PGx)
    What PGx evaluatesInherited genetic variation that may inform medication-related gene-drug associations
    Test formatsSingle-gene tests, multigene panels, and combinatorial tests
    Coverage standardThe test must demonstrate analytical validity, clinical validity, and clinical utility through a required technical assessment
    Germline Test
    Genetic material testedInherited genetic material
    Not includedAcquired genetic alterations
    Tumor-specific alterations

    Covered Testing Indications

    Covered Indication: Medication-Related Gene-Drug Association Testing

    Coverage is limited to pharmacogenomic testing for medication-related gene-drug associations when all of the following are met:

    Covered medication-related gene-drug association testing

    • The testing addresses a medication-related gene-drug association.
    • The test demonstrates analytical validity, clinical validity, and clinical utility through the required technical assessment.
    • The testing meets the applicable Medicare contractor coverage requirements, including the applicable LCD and related article guidance.

    Covered Indication: Limited Medicare Pharmacogenomic Indications

    Medicare coverage is limited to indications supported by applicable contractor guidance:

    Non-Covered Services

    The following services are not covered: IDgenetix, CPT 0411U; GeneSight Psychotropic, CPT 0345U; and pharmacogenomics testing for Medicaid and Commercial members. Codes 0411U and 0345U are investigational and experimental for all lines of business, and CPT 0419U is non-covered because it is outside the relevant gene-drug association table.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyPharmacogenomics Testing, Behavioral Health for Medicare
    Policy CodePolicy 30.0
    Change TypeModified
    Effective DateN/A
    Last ReviewMay 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for pharmacogenomics testing through Pres Online.
    SourceLink
    On This Page
    Coverage CriteriaCovered, Non-Covered, and Managed CodesAuthorization, Documentation, and Billing ActionsPolicy BackgroundKey TermsCovered Testing IndicationsNon-Covered Services
    Codes 81225, 81374, 81335, and 0411U do not require prior authorization under the current policy configuration.
  1. Testing is not used as the sole basis for clinical decision-making regarding prescription medications.
  2. Billing Rule

    Proprietary Test PA and Coverage Handling

    Proprietary-test authorization and coverage depend on the specific code and line of business. IDgenetix (0411U) was previously subject to Medicare case-by-case review; the current review maintains investigational and experimental handling for all lines of business and identifies 0411U as having no prior-authorization requirement.

    • IDgenetix (0411U) is non-covered/investigational and experimental for Medicare, Commercial, and Medicaid.
    • GeneSight Psychotropic (0345U) is investigational and experimental for all lines of business and has no prior-authorization requirement under the current configuration.
    • Do not submit 0411U or 0345U as covered services merely because a prior authorization request is submitted.
    Prior Authorization

    Codes Requiring Prior Authorization

    Prior authorization is required for the applicable pharmacogenomics codes identified in the May 20, 2026 review. Submit the request before testing or claim submission unless a stated exception applies.

    • 81226, 81381, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 81479, 81227, 81231, 81232, 81247, 0286U, 81401, 81406, 81283, 81306, 81328, 81350, 81355, 0029U, 0349U, 0392U, 0423U, 0193U, 81230, 81346, 81407, 0031U, 0032U, 0419U, 0030U, and 0034U.
    • Pending PLA codes 0173U and 0175U also require prior authorization for all lines of business.
    Prior Authorization

    81335 Specialty Exception

    Code 81335 has a specialty-specific exception. Rheumatology and Gastroenterology may bypass the prior-authorization requirement; all other specialties must obtain prior authorization.

    • Applies to all lines of business.
    • Verify the billing specialty before submitting or bypassing authorization.
    Documentation Required

    Technical Assessment Required

    The test must be supported by a technical assessment demonstrating analytical validity, clinical validity, and clinical utility before it can be considered reasonable and necessary for coverage.

    • Maintain technical-assessment documentation for review.
    • PGx tests are germline tests and must also comply with applicable germline-testing policies.
    Prior Authorization

    Submit Through Pres Online

    Submit the prior-authorization request through Pres Online before performing the test.

    • Pres Online: https://ds.phs.org/preslogin/index.jsp
    Documentation Required

    Supporting Clinical Documentation

    Maintain documentation supporting coverage under the external guidelines or references followed by Presbyterian, and provide it when requested.

    • Providers are expected to maintain or have access to appropriate supporting documentation.
    • Relevant sources may include applicable LCDs, NCDs, MCG, NCCN, or other referenced guidelines.
    Documentation Required

    Additional Medical-Necessity Information

    When a member does not meet the stated guideline criteria, submit additional information supporting medical necessity for medical-director review.

    • Additional medical-necessity information is welcome and may be considered in reviewing the case.
    • The policy is a coverage guideline, not a treatment guide.
    Denial Risk

    Insufficient Validity or Utility Evidence

    Coverage may be denied when the required evidence is insufficient to demonstrate analytical validity, clinical validity, or clinical utility.

    • Ensure the technical assessment supports all three validity and utility elements.
    • Insufficient evidence may prevent the test from being considered reasonable and necessary.
    Denial Risk

    Explicitly Non-Covered Tests

    The following tests are explicitly non-covered or investigational and experimental across the identified lines of business.

    • IDgenetix — 0411U
    • GeneSight Psychotropic — 0345U
    • 0419U — non-covered pharmacogenomic code
    Denial Risk

    Do Not Use Testing as the Sole Prescribing Basis

    Pharmacogenomic testing must not be the sole basis for clinical decision-making regarding prescription medications.

    • Integrate results with the member’s clinical presentation, treatment history, and other relevant clinical information.
    Denial Risk

    Investigational or Non-Covered Pharmacogenomic Codes

    Codes 0411U, 0345U, and 0419U are treated as investigational, experimental, or non-covered according to the applicable configuration and line of business.

    • Claims for 0411U and 0345U are maintained as investigational and experimental for all lines of business.
    • 0419U is non-covered and requires prior authorization under the current code list.
    Prior Authorization

    Returned PLA Codes Require Prior Authorization

    PLA codes 0173U and 0175U were returned to Presbyterian management and require prior authorization for all lines of business.

    • Obtain authorization before claim submission.
    • These codes were returned from the external LBM policy because automatic denial could conflict with applicable requirements.
    Billing Rule

    Non-Medicare Benefit Limitation

    Coverage is generally non-covered for Commercial and Medicaid members because pharmacogenomics testing is considered investigational. Medicare coverage is limited to the applicable Medicare indications and policy criteria.

    • Do not assume Medicare coverage extends to Commercial or Medicaid.
    • Medicare claims remain subject to the policy’s coverage criteria, technical-assessment requirements, and prior-authorization rules.
    Prior Authorization

    Provider Action: 81335 Specialty Bypass

    For code 81335, providers in Rheumatology and Gastroenterology may bypass prior authorization. Providers in all other specialties must obtain prior authorization.

    • The bypass applies for all lines of business.
    • Confirm the specialty associated with the service before bypassing authorization.
    Tumor-specific genetic alterations are not the focus of a germline test
    I&E
    MeaningInvestigational and experimental
    Benefit treatmentThe test is not covered under the applicable benefit
    Current examplesCodes 0411U and 0345U are configured as investigational and experimental for all lines of business
    LBM
    MeaningLaboratory Benefit Management policy or program
    Prior managementCertain laboratory codes were previously managed under the LBM policy
    Returned codesCodes 0173U and 0175U were returned to this policy for PHP management and require prior authorization
    ALOB
    MeaningAll lines of business
    Included line of businessMedicare
    Included line of businessCommercial and Medicaid

    Limited Medicare pharmacogenomic indications

    • The member has Medicare coverage.
    • The indication is supported by applicable Novitas or Wisconsin Medicare pharmacogenomics guidance.